Marker Therapeutics FY2024 net loss $10.7M; MT-601 78% response rate in lymphoma

Marker Therapeutics, Inc.

2025-Q1 EPS reported -$0.40 revenue$349,104

Net loss of $10.7M for FY2024 vs $8.2M in FY2023; R&D expense $13.5M, G&A $4.2M.
Cash and equivalents $19.2M at Dec 31, 2024; funds operations into Q1 2026 without additional grants.
Phase 1 APOLLO study: MT-601 (neldaleucel) achieved 78% objective response rate (7/9) with 44.4% complete responses; well-tolerated.
Secured $13M+ in non-dilutive funding from CPRIT ($9.5M) and NIH SBIR ($2M) for pancreatic and lymphoma programs.
December 2024 private placement raised $16.1M from new and existing investors including Blue Owl, NEA, Aisling Capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.